Literature DB >> 25545319

Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience.

Sofía de la Serna1, Ramón Vilana, Santiago Sánchez-Cabús, David Calatayud, Joana Ferrer, Victor Molina, Constantino Fondevila, Jordi Bruix, Josep Fuster, Juan-Carlos García-Valdecasas.   

Abstract

INTRODUCTION: In selected patients, radiofrequency ablation (RFA) is a well-established treatment for hepatocellular carcinoma (HCC). However, subcapsular or lesions close to adjacent viscera preclude a percutaneous approach. In this setting laparoscopic-RFA (LRFA) is a potential alternative. The aim of this study was to analyse the safety and feasibility of LRFA in patients with HCC. PATIENTS AND METHODS: Retrospective study of patients with HCC meeting strict inclusion criteria who underwent LRFA at a single Institution from December 2000 to March 2013.
RESULTS: Forty-one patients underwent 42 LRFA of 51 nodules. The median size of the nodule was 2.5 (range 1.2-4.7) cm. Thirty-one tumours were subcapsular and 17 located near the gallbladder. Major complications occurred in 17 patients. The initial complete response (ICR) rate was 94% and was lower among tumours located adjacent to the gallbladder. At the end of the follow-up period, the sustained complete response (SCR) rate was 70% and was lower in tumours adjacent to the gallbladder while increased for subcapsular tumours. The 1-, 3- and 5-year overall survival rate was 92.6%, 64.5% and 43%, respectively.
CONCLUSION: LRFA of HCC is safe, feasible and achieves excellent results in selected patients. LRFA should be the first-line technique for subcapsular lesions as it minimizes the risk of tumoural seeding and improves ICR. Proximity to gallbladder interferes in treatment efficacy (lower rate of ICR and lower rate of SCR).
© 2014 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2014        PMID: 25545319      PMCID: PMC4402048          DOI: 10.1111/hpb.12379

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  28 in total

1.  Needle track seeding following percutaneous procedures for hepatocellular carcinoma.

Authors:  Giuseppe Cabibbo; Antonio Craxì
Journal:  World J Hepatol       Date:  2009-10-31

2.  Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.

Authors:  Ryosuke Tateishi; Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Yukihiro Koike; Tomonori Fujishima; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

3.  Gallbladder metastasis from hepatocellular carcinoma: Report of a case and review of literature.

Authors:  Masaki Wakasugi; Shigeyuki Ueshima; Hiroki Akamatsu; Masayuki Tori; Masahide Oshita; Masahiko Tsujimoto; Toshirou Nishida
Journal:  Int J Surg Case Rep       Date:  2012-06-01

4.  Case-matched analysis of totally laparoscopic versus open liver resection for HCC: short and middle term results.

Authors:  Luca Aldrighetti; Eleonora Guzzetti; Carlo Pulitanò; Federica Cipriani; Marco Catena; Michele Paganelli; Gianfranco Ferla
Journal:  J Surg Oncol       Date:  2010-07-01       Impact factor: 3.454

5.  Haemodynamic effects of pneumoperitoneum and the influence of posture during anaesthesia for laparoscopic surgery.

Authors:  S Odeberg; O Ljungqvist; T Svenberg; P Gannedahl; M Bäckdahl; A von Rosen; A Sollevi
Journal:  Acta Anaesthesiol Scand       Date:  1994-04       Impact factor: 2.105

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

7.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

Authors:  Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Chao-Wei Hsu; Yi-Cheng Chen
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

8.  Laparoscopic US-guided radiofrequency ablation of unresectable hepatocellular carcinoma in liver cirrhosis: feasibility and clinical outcome.

Authors:  Marco Casaccia; Enzo Andorno; Ilaria Nardi; Bianca Troilo; Gabriele Barabino; Gregorio Santori; Umberto Valente
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2008-12       Impact factor: 1.878

9.  Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: a cohort study.

Authors:  Umberto Cillo; Alessandro Vitale; Davide Dupuis; Stefano Corso; Daniele Neri; Francesco D'Amico; Enrico Gringeri; Fabio Farinati; Valter Vincenzi; Giacomo Zanus
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  16 in total

1.  Long-term outcome of laparoscopic ablation therapies for unresectable hepatocellular carcinoma: a single European center experience of 426 patients.

Authors:  Roberto Santambrogio; Matteo Barabino; Savino Bruno; Mara Costa; Andrea Pisani Ceretti; Maria Rachele Angiolini; Massimo Zuin; Franca Meloni; Enrico Opocher
Journal:  Surg Endosc       Date:  2015-08-15       Impact factor: 4.584

Review 2.  New horizons in ablation therapy for hepatocellular carcinoma.

Authors:  Jacob Freedman; Henrik Nilsson; Eduard Jonas
Journal:  Hepat Oncol       Date:  2015-11-06

Review 3.  Microwave ablation in primary and secondary liver tumours: technical and clinical approaches.

Authors:  Maria Franca Meloni; Jason Chiang; Paul F Laeseke; Christoph F Dietrich; Angela Sannino; Marco Solbiati; Elisabetta Nocerino; Christopher L Brace; Fred T Lee
Journal:  Int J Hyperthermia       Date:  2016-08-02       Impact factor: 3.914

4.  Comparison of Laparoscopic Microwave to Radiofrequency Ablation of Small Hepatocellular Carcinoma (≤3 cm).

Authors:  Roberto Santambrogio; Jason Chiang; Matteo Barabino; Franca Maria Meloni; Emanuela Bertolini; Fabio Melchiorre; Enrico Opocher
Journal:  Ann Surg Oncol       Date:  2016-08-31       Impact factor: 5.344

Review 5.  Laparoscopic thermoablation for hepatocellular carcinoma in patients with liver cirrhosis: an effective procedure for tricky tumors.

Authors:  Roberto Santambrogio; Matteo Barabino; Valentina D'Alessandro; Elisa Galfrascoli; Marco Antonio Zappa; Gaetano Piccolo; Massimo Zuin; Enrico Opocher
Journal:  Med Oncol       Date:  2020-03-19       Impact factor: 3.064

6.  Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.

Authors:  Bin Qiu; Meng-Fei Zhao; Zhen-Dong Yue; Hong-Wei Zhao; Lei Wang; Zhen-Hua Fan; Fu-Liang He; Shan Dai; Jian-Nan Yao; Fu-Quan Liu
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

7.  Percutaneous thermal ablation of subcapsular hepatocellular carcinomas: influence of tumor-surface contact and protrusion on therapeutic efficacy and safety.

Authors:  Akeanong Worakitsitisatorn; David S Lu; Min Woo Lee; Nazanin H Asvadi; Amin Moshksar; Alexander D Yuen; Justin McWilliams; Steven S Raman
Journal:  Eur Radiol       Date:  2019-12-10       Impact factor: 5.315

Review 8.  A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma.

Authors:  Yaoping Shi; Bo Zhai
Journal:  Gastrointest Tumors       Date:  2016-04-28

9.  Laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for subphrenic hepatocellular carcinoma.

Authors:  Min Hwan Kwak; Min Woo Lee; Seong Eun Ko; Hyunchul Rhim; Tae Wook Kang; Kyoung Doo Song; Jong Man Kim; Gyu-Seong Choi
Journal:  Ultrasonography       Date:  2022-02-09

10.  Laparoscopic Radiofrequency Ablation for Large Subcapsular Hepatic Hemangiomas: Technical and Clinical Outcomes.

Authors:  Jun Gao; Jian-Song Ji; Xue-Mei Ding; Shan Ke; Zong-Hai Xin; Chun-Min Ning; Shi-Gang Guo; Xiao-Long Li; Yong-Hong Dong; Wen-Bing Sun
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.